Radiopharmaceuticals, Reengineered.

Innovative, therapeutic, and diagnostic targeted radiopharmaceuticals filling critical gaps in oncologic care.


As cancer rates rise globally, highly effective, patient-centric treatment options are more critical than ever before.  Personalized treatment, targeting tumors based on their unique chemistry, cuts side effects and improves outcomes. Today, therapeutics targeting SST receptor subtype 2 (SSTR-2) protein expressing tumors, like Neuroendocrine Tumors (NETs), Hürthle Cell Thyroid cancer, non-small cell lung cancer, Nasopharyngeal Cancer, and Glioblastoma Multiforme, show comparatively low response rates, due in part to rapid blood clearance and cautious dosing to avoid potential renal toxicity.

EvaThera Theranostics are a new generation of Evans Blue-based molecules with strong affinity for albumin which:

  • Extend the blood half-life of targeting radiopharmaceuticals.
  • Decrease their blood clearance and improve uptake with less toxicity.
  • Promise improved therapeutic and diagnostic outcomes in SSTR2 and integrin expressing cancer patients.

For late-stage neuroendocrine tumors

EBTATE is a novel “three-in-one” therapeutic, composed of a tumor targeting octreotate peptide, Evans blue dye, and a chelator carrying a tumor-killing radionuclide 177Lu.

For integrin expressing cancers.

EBRGD has been developed for the treatment of integrin expressing cancers, including Glioblastoma Multiforme and Non-Small Cell Lung Cancer (NSCLC). EBRGD also improves efficacy synergistically when used in tandem with checkpoint inhibitor immunotherapy.

Be the First to Know

Visit us on LinkedIn and Connect with Us.


In a 3-year follow-up to MTTI’s 177 Lu-EBTATE research against gastroenteropathic-neuroendocrine tumors, EvaThera has found a favorable survival outcome disease control rate of 86% and encouraging median 36-month Progression Free survival.1

1 Jiang Y, Liu Q, Wang G, et al. Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. Theranostics. 2022;12(15):6437-6445.

Inspiring hope

Rare cancers, including late-stage NETs and integrin expressing tumors, exert a devastating impact on the lives of patients, our healthcare system, and society at large. Tumors are often discovered late, carry short prognoses, and are difficult to treat, causing significant physical and emotional pain, loss of life, and major expense.

As pioneers in radiopharmaceutical research, Molecular Targeting Technologies, Inc. (MTTI) strives to create radiopharmaceutical “theranostics” (therapeutics/diagnostics) that deliver tangible value in more effective treatments, more lives saved, and lower burden to health systems.

Innovate with us.

We’re passionate about advancing the future of radiopharmaceuticals through next-generation theranostic technologies. If you are too, we’d love to hear from you.

© 2023 Molecular Targeting Technologies, INC. All Rights Reserved.